This Amendment No. 28 is being filed jointly by Golden Meditech Stem Cells (BVI) Company Limited (GM Stem Cells), Golden Meditech Holdings Limited (Golden Meditech), Bio Garden Inc. (Bio Garden), Magnum Opus 3 International Holdings Limited (MO3) and Yuen Kam (Mr. Kam). GM Stem Cells, Golden Meditech, Bio Garden, MO3 and Mr. Kam are collectively referred to as the Reporting Persons.
This Amendment No. 28 amends and supplements the statement on Schedule 13D jointly filed with the Securities and Exchange Commission on July 9, 2009 by GM Stem Cells and Golden Meditech, as previously amended and supplemented by amendments to Schedule 13D filed on June 23, 2011, September 30, 2011, April 12, 2012, May 2, 2012, October 4, 2012, July 11, 2013, August 25, 2014, April 27, 2015, May 4, 2015, May 8, 2015, July 27, 2015, August 6, 2015, August 26, 2015, October 26, 2015, November 3, 2015, November 5, 2015, November 13, 2015, November 30, 2015, December 7, 2015, January 7, 2016, September 1, 2016, October 31, 2016, December 30, 2016, April 6, 2017, April 10, 2017, April 13, 2017 and November 14, 2017 (as so amended, the Original Schedule 13D). Capitalized terms used but not defined herein shall have the meanings ascribed to them in the Original Schedule 13D.
Item 4.
Purpose of Transaction
Item 4 of the Original Schedule 13D is hereby amended and supplemented by adding the following at the end thereof:
On January 31, 2018, the sale and purchase of the GM Shares was completed under the GM New Sale Agreement, as amended by the GM Supplemental Agreement. Upon and following such completion, GM Stem Cells ceased to own any of the GM Shares.
Item 5.
Material to be Filed as Exhibits.
Item 5 of the Original Schedule 13D is hereby amended and restated in its entirety to read as follows:
(a) (b) As a result of the transactions described in Item 4, as of the date of this Amendment No. 28, each Reporting Person no longer beneficially owns any Ordinary Shares and, as such, each Reporting Person no longer has any voting or dispositive power over any Ordinary Shares.
(c) To the best knowledge of the Reporting Persons, except as described herein, none of the Reporting Persons has effected any transactions in the Ordinary Shares during the past 60 days prior to the filing of this Amendment No. 28.
(d) Not applicable.
(e) As a result of the transactions described in Item 4, as of the date of this Amendment No. 28, each of the Reporting Persons ceased to be the beneficial owner of more than five percent of any Ordinary Shares. Therefore, this Amendment No. 28 constitutes the final amendment to the Original Schedule 13D, as amended.
7